147 related articles for article (PubMed ID: 37816842)
1. Generation of evidence-based carboplatin dosing guidelines for neonates and infants.
Barnett S; Makin G; Tweddle DA; Osborne C; Veal GJ
Br J Cancer; 2023 Nov; 129(11):1773-1779. PubMed ID: 37816842
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin therapeutic monitoring in preterm and full-term neonates.
Veal GJ; Errington J; Hayden J; Hobin D; Murphy D; Dommett RM; Tweddle DA; Jenkinson H; Picton S
Eur J Cancer; 2015 Sep; 51(14):2022-30. PubMed ID: 26232270
[TBL] [Abstract][Full Text] [Related]
3. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
5. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients.
Peng B; Boddy AV; Cole M; Pearson AD; Chatelut E; Rubie H; Newell DR
Eur J Cancer; 1995 Oct; 31A(11):1804-10. PubMed ID: 8541105
[TBL] [Abstract][Full Text] [Related]
6. Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients.
Barnett S; Hellmann F; Parke E; Makin G; Tweddle DA; Osborne C; Hempel G; Veal GJ
Eur J Cancer; 2022 Mar; 164():127-136. PubMed ID: 34657763
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma.
Picton SV; Keeble J; Holden V; Errington J; Boddy AV; Veal GJ
Cancer Chemother Pharmacol; 2009 Mar; 63(4):749-52. PubMed ID: 18607591
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.
Duong JK; Veal GJ; Nath CE; Shaw PJ; Errington J; Ladenstein R; Boddy AV
Br J Clin Pharmacol; 2019 Jan; 85(1):136-146. PubMed ID: 30261554
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance.
Etienne MC; Leger F; Pivot X; Chatelut E; Bensadoun RJ; Guardiola E; Renée N; Magné N; Canal P; Milano G
Ann Oncol; 2003 Apr; 14(4):643-7. PubMed ID: 12649114
[TBL] [Abstract][Full Text] [Related]
10. Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom.
Barnett S; Kong J; Makin G; Veal GJ
Br J Clin Pharmacol; 2021 Feb; 87(2):256-262. PubMed ID: 32519769
[TBL] [Abstract][Full Text] [Related]
11. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108
[TBL] [Abstract][Full Text] [Related]
12. Phase I evaluation of carboplatin by use of a dosing strategy based on a targeted area under the platinum concentration-versus-time curve and individual glomerular filtration rate in cats with tumors.
Bailey DB; Rassnick KM; Dykes NL; Pendyala L
Am J Vet Res; 2009 Jun; 70(6):770-6. PubMed ID: 19496668
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two methods for carboplatin dosing in children with retinoblastoma.
Allen S; Wilson MW; Watkins A; Billups C; Qaddoumi I; Haik BH; Rodriguez-Galindo C
Pediatr Blood Cancer; 2010 Jul; 55(1):47-54. PubMed ID: 20486170
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study.
Moeung S; Chevreau C; Broutin S; Guitton J; Lelièvre B; Ciccolini J; Massart C; Fléchon A; Delva R; Gravis G; Lotz JP; Bay JO; Gross-Goupil M; Paci A; Marsili S; Malard L; Chatelut E; Thomas F
Clin Cancer Res; 2017 Dec; 23(23):7171-7179. PubMed ID: 28928162
[No Abstract] [Full Text] [Related]
16. Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy.
Veal GJ; English MW; Grundy RG; Shakespeare C; Glaser A; Waters F; Holden V; O'Meara A; Michalski A; Howe K; Cole S; Boddy AV
Cancer Chemother Pharmacol; 2004 Oct; 54(4):295-300. PubMed ID: 15133627
[TBL] [Abstract][Full Text] [Related]
17. Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review.
Morrow A; Garland C; Yang F; De Luna M; Herrington JD
J Oncol Pharm Pract; 2019 Oct; 25(7):1651-1657. PubMed ID: 30336729
[TBL] [Abstract][Full Text] [Related]
18. Individual dosing of carboplatin based on drug monitoring in children receiving high-dose chemotherapy.
Rubie H; Doz F; Vassal G; Chastagner P; Gentet JC; Urien S; Bastian G; Drouard-Troalen L; Barberi-Heyob M; Catalin J; Chatelut E;
Eur J Cancer; 2003 Jul; 39(10):1433-8. PubMed ID: 12826047
[TBL] [Abstract][Full Text] [Related]
19. Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial.
Thomas H; Boddy AV; English MW; Hobson R; Imeson J; Lewis I; Morland B; Pearson AD; Pinkerton R; Price L; Stevens M; Newell DR
J Clin Oncol; 2000 Nov; 18(21):3614-21. PubMed ID: 11054434
[TBL] [Abstract][Full Text] [Related]
20. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
